{"id":"ticagrelor-delayed-administration","safety":{"commonSideEffects":[{"rate":"4-6","effect":"Bleeding"},{"rate":"3-5","effect":"Bradycardia"},{"rate":"2-4","effect":"Dyspnea"},{"rate":"1-2","effect":"Ventricular pauses"}]},"_chembl":{"chemblId":"CHEMBL398435","moleculeType":"Small molecule","molecularWeight":"522.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, blocking platelet activation and aggregation. This mechanism reduces the formation of blood clots and is used to prevent stent thrombosis and recurrent cardiovascular events. The delayed administration strategy refers to a dosing regimen approach rather than a mechanistic modification of the drug itself.","oneSentence":"Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation to prevent thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:37.316Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) with delayed loading dose administration"},{"name":"Prevention of stent thrombosis in percutaneous coronary intervention (PCI)"}]},"trialDetails":[{"nctId":"NCT07476898","phase":"PHASE3","title":"Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03-01","conditions":"Stroke","enrollment":864},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT01916902","phase":"PHASE4","title":"Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-02","conditions":"Acute Coronary Syndrome, Coronary Artery Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ticagrelor- Delayed Administration","genericName":"Ticagrelor- Delayed Administration","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation to prevent thrombotic events. Used for Acute coronary syndrome (ACS) with delayed loading dose administration, Prevention of stent thrombosis in percutaneous coronary intervention (PCI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}